Status: Recruiting
Prognostic Significance of ctDNA in HL
Specific somatic mutations using ctDNA will be analyzed in predefined subgroups of cHL (e.g., age \<60 and ≥ 60 years, EBV). These mutations will be correlated with response to the treatment in the first line, in the relapse, during brentuximab vedotin and/or nivolumab treatment. Circulating tumor DNA will be correlated with the extent of tumor mass and chemo/radiotherapy.
Participants needed: 500
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Interni hematologicka klinika FNKVUpdated: Feb 16, 2024Locations: 5
Eligibility criteria
Patients ≥ 18 years with newly histologically confirmed classical Hodgkin lympho... [+1]
Pacients without signing the informed consent